New Insights into the Pathogenesis, Diagnosis, and Management of Mastocytosis

Hematology/Oncology Clinics of North America

Volumn 26, Issue 6, 2012, Pages 1143-1168

  Fuller, Stephen J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Mast cell function; Mastocytosis; Myeloid malignancy; Pathogenesis

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHYMASE; CODEINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; GLUCOCORTICOID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTEINASE; PSORALEN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; STEROID; TOLL LIKE RECEPTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VENOM; ZINC SULFATE;

ADAPTIVE IMMUNITY; ANAPHYLAXIS; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL STRUCTURE; CELL SURVIVAL; CLINICAL EXAMINATION; CLINICAL FEATURE; CYTOGENETICS; CYTOREDUCTIVE SURGERY; DISEASE CLASSIFICATION; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INNATE IMMUNITY; LABORATORY TEST; LANGERHANS CELL; MAST CELL; MASTOCYTOSIS; MEDIATOR RELEASE; OSTEOPENIA; OSTEOPOROSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SKIN CARE; SKIN MANIFESTATION; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; URTICARIA PIGMENTOSA;

HUMANS; MASTOCYTOSIS; PROGNOSIS;

EID: 84868233775     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.08.008     Document Type: Review

References (177)

1. Kitamura Y., Go S., Hatanaka K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 1978, 52(2):447-452.
2. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112(4):946-956.
3. Feger F., Varadaradjalou S., Gao Z., et al. The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol 2002, 23(3):151-158.
4. Hofmann A.M., Abraham S.N. New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr Opin Immunol 2009, 21(6):679-686.
5. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995, 92(23):10560-10564.
6. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12(3):312-314.
7. Fritsche-Polanz R., Jordan J.H., Feix A., et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001, 113(2):357-364.
8. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108(7):2366-2372.
9. Hartmann K., Henz B.M. Mastocytosis: recent advances in defining the disease. Br J Dermatol 2001, 144(4):682-695.
10. Boyano T., Carrascosa T., Val J., et al. Urticaria pigmentosa in monozygotic twins. Arch Dermatol 1990, 126(10):1375-1376.
11. Tang X., Boxer M., Drummond A., et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004, 41(6):e88.
12. Zhang L.Y., Smith M.L., Schultheis B., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006, 30(4):373-378.
13. Hartmann K., Wardelmann E., Ma Y., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005, 129(3):1042-1046.
14. Swerdlow S.H. International Agency for Research on Cancer., World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon (France). 4th edition.
15. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(3):179-190.
16. Supajatura V., Ushio H., Nakao A., et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002, 109(10):1351-1359.
17. Hirai Y., Kuwada M., Yasuhara T., et al. A new mast cell degranulating peptide homologous to mastoparan in the venom of Japanese hornet (Vespa xanthoptera). Chem Pharm Bull (Tokyo) 1979, 27(8):1945-1946.
18. Demeure C.E., Brahimi K., Hacini F., et al. Anopheles mosquito bites activate cutaneous mast cells leading to a local inflammatory response and lymph node hyperplasia. J Immunol 2005, 174(7):3932-3940.
19. Abraham S.N., St John A.L. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010, 10(6):440-452.
20. Ryan J.J., Kashyap M., Bailey D., et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 2007, 27(1):15-32.
21. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005, 23:749-786.
22. Malaviya R., Ikeda T., Ross E., et al. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996, 381(6577):77-80.
23. Malaviya R., Ross E.A., MacGregor J.I., et al. Mast cell phagocytosis of FimH-expressing enterobacteria. J Immunol 1994, 152(4):1907-1914.
24. Kalesnikoff J., Galli S.J. New developments in mast cell biology. Nat Immunol 2008, 9(11):1215-1223.
25. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 1997, 61(3):233-245.
26. Pejler G., Abrink M., Ringvall M., et al. Mast cell proteases. Adv Immunol 2007, 95:167-255.
27. Caughey G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007, 217:141-154.
28. Irani A.M., Schwartz L.B. Human mast cell heterogeneity. Allergy Proc 1994, 15(6):303-308.
29. Schwartz L.B. Mediators of human mast cells and human mast cell subsets. Ann Allergy 1987, 58(4):226-235.
30. Burke S.M., Issekutz T.B., Mohan K., et al. Human mast cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism. Blood 2008, 111(12):5467-5476.
31. Di Nardo A., Vitiello A., Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003, 170(5):2274-2278.
32. McLachlan J.B., Hart J.P., Pizzo S.V., et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol 2003, 4(12):1199-1205.
33. Jawdat D.M., Rowden G., Marshall J.S. Mast cells have a pivotal role in TNF-independent lymph node hypertrophy and the mobilization of Langerhans cells in response to bacterial peptidoglycan. J Immunol 2006, 177(3):1755-1762.
34. Stelekati E., Bahri R., D'Orlando O., et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009, 31(4):665-676.
35. Kawakami T., Galli S.J. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002, 2(10):773-786.
36. Secor V.H., Secor W.E., Gutekunst C.A., et al. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000, 191(5):813-822.
37. Lee D.M., Friend D.S., Gurish M.F., et al. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297(5587):1689-1692.
38. Chen R., Ning G., Zhao M.L., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001, 108(8):1151-1158.
39. Grimbaldeston M.A., Nakae S., Kalesnikoff J., et al. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 2007, 8(10):1095-1104.
40. Lu L.F., Lind E.F., Gondek D.C., et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442(7106):997-1002.
41. Nabel G., Galli S.J., Dvorak A.M., et al. Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature 1981, 291(5813):332-334.
42. Kirshenbaum A.S., Kessler S.W., Goff J.P., et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991, 146(5):1410-1415.
43. Rodewald H.R., Dessing M., Dvorak A.M., et al. Identification of a committed precursor for the mast cell lineage. Science 1996, 271(5250):818-822.
44. Chen C.C., Grimbaldeston M.A., Tsai M., et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 2005, 102(32):11408-11413.
45. Okayama Y., Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006, 34(2):97-115.
46. Nakahata T., Toru H. Cytokines regulate development of human mast cells from hematopoietic progenitors. Int J Hematol 2002, 75(4):350-356.
47. Yin T., Taga T., Tsang M.L., et al. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol 1993, 151(5):2555-2561.
48. Meininger C.J., Yano H., Rottapel R., et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood 1992, 79(4):958-963.
49. Matsuura N., Zetter B.R. Stimulation of mast cell chemotaxis by interleukin 3. J Exp Med 1989, 170(4):1421-1426.
50. Toru H., Eguchi M., Matsumoto R., et al. Interleukin-4 promotes the development of tryptase and chymase double-positive human mast cells accompanied by cell maturation. Blood 1998, 91(1):187-195.
51. Toru H., Ra C., Nonoyama S., et al. Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol 1996, 8(9):1367-1373.
52. Xia H.Z., Du Z., Craig S., et al. Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol 1997, 159(6):2911-2921.
53. Kirshenbaum A.S., Swindle E., Kulka M., et al. Effect of lipopolysaccharide (LPS) and peptidoglycan (PGN) on human mast cell numbers, cytokine production, and protease composition. BMC Immunol 2008, 9:45.
54. Gebhardt T., Lorentz A., Detmer F., et al. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 2005, 54(7):928-934.
55. Roskoski R. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 2005, 337(1):1-13.
56. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003, 4(4):313-319.
57. Ali K., Bilancio A., Thomas M., et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004, 431(7011):1007-1011.
58. Li Z., Jiang H., Xie W., et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000, 287(5455):1046-1049.
59. Shelburne C.P., McCoy M.E., Piekorz R., et al. Stat5 expression is critical for mast cell development and survival. Blood 2003, 102(4):1290-1297.
60. Alexander W.S., Lyman S.D., Wagner E.F. Expression of functional c-kit receptors rescues the genetic defect of W mutant mast cells. EMBO J 1991, 10(12):3683-3691.
61. Mekori Y.A., Gilfillan A.M., Akin C., et al. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J Clin Immunol 2001, 21(3):171-174.
62. Baghestanian M., Jordan J.H., Kiener H.P., et al. Activation of human mast cells through stem cell factor receptor (KIT) is associated with expression of bcl-2. Int Arch Allergy Immunol 2002, 129(3):228-236.
63. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91(2):231-241.
64. Blume-Jensen P., Janknecht R., Hunter T. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136. Curr Biol 1998, 8(13):779-782.
65. del Peso L., Gonzalez-Garcia M., Page C., et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278(5338):687-689.
66. Alfredsson J., Puthalakath H., Martin H., et al. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ 2005, 12(2):136-144.
67. Furitsu T., Tsujimura T., Tono T., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993, 92(4):1736-1744.
68. Piao X., Bernstein A. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996, 87(8):3117-3123.
69. Longley B.J., Reguera M.J., Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001, 25(7):571-576.
70. Feger F., Ribadeau Dumas A., Leriche L., et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002, 127(2):110-114.
71. Bodemer C., Hermine O., Palmerini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130(3):804-815.
72. Mayerhofer M., Gleixner K.V., Hoelbl A., et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008, 180(8):5466-5476.
73. Gleixner K.V., Mayerhofer M., Cerny-Reiterer S., et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011, 118(7):1885-1898.
74. Tefferi A., Levine R.L., Lim K.H., et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, 23(5):900-904.
75. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103(8):3222-3225.
76. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999, 96(4):1609-1614.
77. Sotlar K., Escribano L., Landt O., et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003, 162(3):737-746.
78. Yanagihori H., Oyama N., Nakamura K., et al. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005, 7(2):252-257.
79. Buttner C., Henz B.M., Welker P., et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998, 111(6):1227-1231.
80. Kettelhut B.V., Metcalfe D.D. Pediatric mastocytosis. J Invest Dermatol 1991, 96(Suppl 3):15S-18S. [discussion: 8S, 60S-5S].
81. Azana J.M., Torrelo A., Mediero I.G., et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol 1994, 11(2):102-106.
82. Middelkamp Hup M.A., Heide R., Tank B., et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol 2002, 16(2):115-120.
83. Czarnetzki B.M., Kolde G., Schoemann A., et al. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988, 18(1 Pt 1):45-51.
84. Parwaresch M.R., Horny H.P., Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985, 179(4-5):439-461.
85. Hannaford R., Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol 2001, 42(1):15-21.
86. Pardanani A., Akin C., Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006, 19(3):595-615.
87. Horny H.P., Parwaresch M.R., Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985, 16(8):808-814.
88. Horny H.P., Kaiserling E., Campbell M., et al. Liver findings in generalized mastocytosis. A clinicopathologic study. Cancer 1989, 63(3):532-538.
89. Horny H.P., Ruck M.T., Kaiserling E. Spleen findings in generalized mastocytosis. A clinicopathologic study. Cancer 1992, 70(2):459-468.
90. Horny H.P., Kaiserling E., Parwaresch M.R., et al. Lymph node findings in generalized mastocytosis. Histopathology 1992, 21(5):439-446.
91. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
92. Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001, 25(7):519-528.
93. Topar G., Staudacher C., Geisen F., et al. Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 1998, 109(3):279-285.
94. Scheck O., Horny H.P., Ruck P., et al. Solitary mastocytoma of the eyelid. A case report with special reference to the immunocytology of human tissue mast cells, and a review of the literature. Virchows Arch A Pathol Anat Histopathol 1987, 412(1):31-36.
95. Orkin M., Good R.A., Clawson C.C., et al. Bullous mastocytosis. Arch Dermatol 1970, 101(5):547-564.
96. Golitz L.E., Weston W.L., Lane A.T. Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme. Pediatr Dermatol 1984, 1(4):288-294.
97. Horny H.P., Sotlar K., Sperr W.R., et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004, 57(6):604-608.
98. Lim K.H., Tefferi A., Lasho T.L., et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113(23):5727-5736.
99. Castells M., Austen K.F. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002, 127(2):147-152.
100. Cherner J.A., Jensen R.T., Dubois A., et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988, 95(3):657-667.
101. Hermine O., Lortholary O., Leventhal P.S., et al. Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One 2008, 3(5):e2266.
102. Horny H.P., Ruck M., Wehrmann M., et al. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990, 76(2):186-193.
103. Travis W.D., Li C.Y., Yam L.T., et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988, 62(5):965-972.
104. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114(18):3769-3772.
105. Brcic L., Vuletic L.B., Stepan J., et al. Mast-cell sarcoma of the tibia. J Clin Pathol 2007, 60(4):424-425.
106. Horny H.P., Parwaresch M.R., Kaiserling E., et al. Mast cell sarcoma of the larynx. J Clin Pathol 1986, 39(6):596-602.
107. Kojima M., Nakamura S., Itoh H., et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 1999, 12(7):739-743.
108. Charrette E.E., Mariano A.V., Laforet E.G. Solitary mast cell "tumor" of lung. Its place in the spectrum of mast cell disease. Arch Intern Med 1966, 118(4):358-362.
109. Sherwin R.P., Kern W.H., Jones J.C. Solitary mast cell granuloma (histiocytoma) of the lung; a histopathologic, tissue culture and time-lapse cinematographic study. Cancer 1965, 18:634-641.
110. Kudo H., Morinaga S., Shimosato Y., et al. Solitary mast cell tumor of the lung. Cancer 1988, 61(10):2089-2094.
111. Barete S., Assous N., de Gennes C., et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010, 69(10):1838-1841.
112. Escribano L., Alvarez-Twose I., Sanchez-Munoz L., et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009, 124(3):514-521.
113. van der Veer E., van der Goot W., de Monchy J.G., et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012, 67(3):431-438.
114. Tharp M.D., Glass M.J., Seelig L.L. Ultrastructural morphometric analysis of human mast cells in normal skin and pathological cutaneous lesions. J Cutan Pathol 1988, 15(2):78-83.
115. Weidner N., Austen K.F. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol 1991, 96(Suppl 3):26S-30S. [discussion: S-1S, 60S-5S].
116. Travis W.D., Li C.Y., Bergstralh E.J., et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988, 67(6):345-368.
117. Garriga M.M., Friedman M.M., Metcalfe D.D. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol 1988, 82(3 Pt 1):425-432.
118. Sperr W.R., Drach J., Hauswirth A.W., et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005, 11(19 Pt 1):6787-6792.
119. Krokowski M., Sotlar K., Krauth M.T., et al. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol 2005, 124(4):560-568.
120. Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001, 25(7):543-551.
121. Horny H.P., Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002, 127(2):115-117.
122. Sperr W.R., Escribano L., Jordan J.H., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001, 25(7):529-536.
123. Li W.V., Kapadia S.B., Sonmez-Alpan E., et al. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996, 9(10):982-988.
124. Patnaik M.M., Rindos M., Kouides P.A., et al. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007, 131(5):784-791.
125. Sperr W.R., Jordan J.H., Fiegl M., et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002, 128(2):136-141.
126. Sperr W.R., El-Samahi A., Kundi M., et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009, 39(10):914-923.
127. Sotlar K., Marafioti T., Griesser H., et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000, 53(4):188-193.
128. Valent P., Akin C., Sperr W.R., et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46(1):35-48.
129. Pullarkat V., Bedell V., Kim Y., et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007, 31(2):261-265.
130. Thachil J., Hawkins S., Woodcock B. JAK2-positive myeloproliferative neoplasm co-existing with systemic mastocytosis. Br J Haematol 2011, 152(6):675.
131. Bain B.J. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004, 77(1):82-85.
132. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101(12):4660-4666.
133. Pardanani A. Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87(4):401-411.
134. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102(9):3093-3096.
135. Florian S., Esterbauer H., Binder T., et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006, 30(9):1201-1205.
136. Valent P., Akin C., Metcalfe D.D. FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis. Eur J Clin Invest 2007, 37(2):153-154.
137. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120(3):680-687.
138. Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011, 12(4):259-270.
139. Welch E.A., Alper J.C., Bogaars H., et al. Treatment of bullous mastocytosis with disodium cromoglycate. J Am Acad Dermatol 1983, 9(3):349-353.
140. Marone G., Spadaro G., Granata F., et al. Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 2001, 25(7):583-594.
141. Kettelhut B.V., Berkebile C., Bradley D., et al. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol 1989, 83(5):866-870.
142. Frieri M., Alling D.W., Metcalfe D.D. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. Am J Med 1985, 78(1):9-14.
143. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
144. Brockow K., Jofer C., Behrendt H., et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63(2):226-232.
145. Worobec A.S., Metcalfe D.D. Mastocytosis: current treatment concepts. Int Arch Allergy Immunol 2002, 127(2):153-155.
146. Butterfield J.H., Kao P.C., Klee G.C., et al. Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization. Mayo Clin Proc 1995, 70(5):481-487.
147. Oude Elberink J.N., de Monchy J.G., Kors J.W., et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997, 99(1 Pt 1):153-154.
148. Pumphrey R.S. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000, 30(8):1144-1150.
149. Desborough J.P., Taylor I., Hattersley A., et al. Massive histamine release in a patient with systemic mastocytosis. Br J Anaesth 1990, 65(6):833-836.
150. Niedoszytko M., de Monchy J., van Doormaal J.J., et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009, 64(9):1237-1245.
151. Marone G., Stellato C. Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy 1992, 30:54-73.
152. Stellato C., Marone G. Mast cells and basophils in adverse reactions to drugs used during general anesthesia. Chem Immunol 1995, 62:108-131.
153. Scott H.W., Parris W.C., Sandidge P.C., et al. Hazards in operative management of patients with systemic mastocytosis. Ann Surg 1983, 197(5):507-514.
154. James P.D., Krafchik B.R., Johnston A.E. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth 1987, 34(5):522-524.
155. Greenblatt E.P., Chen L. Urticaria pigmentosa: an anesthetic challenge. J Clin Anesth 1990, 2(2):108-115.
156. Lerno G., Slaats G., Coenen E., et al. Anaesthetic management of systemic mastocytosis. Br J Anaesth 1990, 65(2):254-257.
157. Borgeat A., Ruetsch Y.A. Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique. Anesth Analg 1998, 86(2):442-444.
158. Mackey S., Pride H.B., Tyler W.B. Diffuse cutaneous mastocytosis. Treatment with oral psoralen plus UV-A. Arch Dermatol 1996, 132(12):1429-1430.
159. Smith M.L., Orton P.W., Chu H., et al. Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol 1990, 7(4):251-255.
160. Lim K.H., Pardanani A., Butterfield J.H., et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84(12):790-794.
161. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992, 326(9):619-623.
162. Casassus P., Caillat-Vigneron N., Martin A., et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002, 119(4):1090-1097.
163. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102(13):4270-4276.
164. Tefferi A., Li C.Y., Butterfield J.H., et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001, 344(4):307-309.
165. Hennessy B., Giles F., Cortes J., et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 2004, 77(3):209-214.
166. Samorapoompichit P., Steiner M., Lucas T., et al. Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs. Leuk Lymphoma 2003, 44(3):509-515.
167. Pardanani A., Elliott M., Reeder T., et al. Imatinib for systemic mast-cell disease. Lancet 2003, 362(9383):535-536.
168. Droogendijk H.J., Kluin-Nelemans H.J., van Doormaal J.J., et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006, 107(2):345-351.
169. Shah N.P., Lee F.Y., Luo R., et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108(1):286-291.
170. Dubreuil P., Letard S., Ciufolini M., et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009, 4(9):e7258.
171. Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85(12):921-925.
172. Growney J.D., Clark J.J., Adelsperger J., et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005, 106(2):721-724.
173. Gleixner K.V., Mayerhofer M., Aichberger K.J., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006, 107(2):752-759.
174. Gotlib J., Berube C., Growney J.D., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106(8):2865-2870.
175. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14(12):3906-3915.
176. Sperr W.R., Horny H.P., Lechner K., et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000, 37(5-6):473-486.
177. Sperr W.R., Walchshofer S., Horny H.P., et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998, 103(3):740-749.